Drug Profile
Amuvatinib - Astex Pharmaceuticals
Alternative Names: Amuvatinib hydrochloride; HPK-56; MP-470; MP-470.HCLLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Montigen
- Developer Astex Pharmaceuticals
- Class Amides; Antineoplastics; Benzofurans; Dioxoles; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action DNA repair inhibitors; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-met inhibitors; Rad51 recombinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Glioblastoma; Small cell lung cancer